Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lisaftoclax × Clear all

Phase

Status

Recruiting 9 Unknown 4 Not yet recruiting 3 Suspended 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Cyclophosphamide 1486 Cisplatin 1419 Paclitaxel 1331 Radiotherapy 1300 Carboplatin 1255 Gemcitabine 1219 Docetaxel 1130 Bevacizumab 1061 Fluorouracil 900 Doxorubicin 793 Dexamethasone 748 Rituximab 742 Capecitabine 734 Oxaliplatin 705 pembrolizumab 677 Etoposide 670 Irinotecan 634 Filgrastim 623 Cytarabine 583 Leucovorin 577 Nivolumab 575 Vincristine 507 Prednisone 474 Cetuximab 474 Bortezomib 472 Trastuzumab 468 Erlotinib Hydrochloride 466 Surveys and Questionnaires 454 Methotrexate 440 Lenalidomide 434

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡